PT1185649E - Promotor do gene da miostatina e inibicao da sua activacao - Google Patents

Promotor do gene da miostatina e inibicao da sua activacao

Info

Publication number: PT1185649E
Authority: PT; Portugal
Prior art keywords: promoter; gene; miostatina; initiation; activation
Prior art date: 1999-06-10

Application number

PT00941296T

Other languages

English (en)

Inventor

Jinshyun R Wu-Wong

Wang Jiahong

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-06-09

Publication date

2005-08-31

2000-06-09 Application filed by Abbott Lab filed Critical Abbott Lab

2005-08-31 Publication of PT1185649E publication Critical patent/PT1185649E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Neurology (AREA)
Virology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

PT00941296T 1999-06-10 2000-06-09 Promotor do gene da miostatina e inibicao da sua activacao PT1185649E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/329,685 US6284882B1 (en)	1999-06-10	1999-06-10	Myostatin gene promoter and inhibition of activation thereof

Publications (1)

Publication Number	Publication Date
PT1185649E true PT1185649E (pt)	2005-08-31

Family

ID=23286552

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT00941296T PT1185649E (pt)	1999-06-10	2000-06-09	Promotor do gene da miostatina e inibicao da sua activacao

Country Status (10)

Country	Link
US (2)	US6284882B1 (pt)
EP (1)	EP1185649B1 (pt)
JP (1)	JP4625602B2 (pt)
AT (1)	ATE293691T1 (pt)
CA (1)	CA2375820C (pt)
DE (1)	DE60019586T2 (pt)
ES (1)	ES2240108T3 (pt)
MX (1)	MXPA01012665A (pt)
PT (1)	PT1185649E (pt)
WO (1)	WO2000077206A2 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0878552A1 (en)	1997-05-13	1998-11-18	Erasmus Universiteit Rotterdam	Molecular detection of chromosome aberrations
JP2002513587A (ja)	1998-05-04	2002-05-14	ダコエーエス	染色体異常を検出するための方法およびプローブ
US6555672B1 (en) *	1998-07-15	2003-04-29	Metamorphix, Inc.	Growth differentiation factor promoter and uses therefor
ZA200003786B (en) *	1999-07-30	2002-01-21	Pfizer Prod Inc	Myostatin regulatory region, nucleotide sequence determination and methods for its use.
US20040248121A1 (en) *	2001-07-11	2004-12-09	Ravi Kambadur	Bioassay for myostatin
ATE496938T1 (de) *	2002-12-20	2011-02-15	Amgen Inc	Myostatin hemmende bindungsstoffe
US9068234B2 (en)	2003-01-21	2015-06-30	Ptc Therapeutics, Inc.	Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) *	2003-01-21	2013-04-23	Ptc Therapeutics, Inc.	Methods and agents for screening for compounds capable of modulating VEGF expression
CA2514184C (en)	2003-01-21	2016-04-12	Ptc Therapeutics, Inc.	Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
JP2007535912A (ja) *	2003-12-31	2007-12-13	シェーリング−プラウ・リミテッド	中和エピトープベースの増殖増強性ワクチン
US20060130157A1 (en)	2004-10-22	2006-06-15	Kevin Wells	Ungulates with genetically modified immune systems
AU2005323087A1 (en)	2004-12-30	2006-07-13	Schering-Plough Pty. Limited	Neutralizing epitope-based growth enhancing vaccine
CA2596506C (en)	2005-02-09	2021-04-06	Avi Biopharma, Inc.	Antisense composition and method for treating muscle atrophy
WO2006102574A2 (en) *	2005-03-23	2006-09-28	Wyeth	Detection of gdf-8 modulating agents
BRPI0609439A2 (pt) *	2005-03-23	2010-04-06	Wyeth Corp	detecção de uma resposta imunológica a agentes moduladores de gdf-8
CA2538208A1 (en) *	2005-05-04	2006-11-04	Universite Laval	Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
JP2009518422A (ja) *	2005-12-06	2009-05-07	アムジェンインコーポレイテッド	ミオスタチン・アンタゴニストの使用
US8426374B1 (en)	2006-05-04	2013-04-23	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Method for modifying myostatin expression
US8283115B1 (en)	2007-06-20	2012-10-09	Ptc Therapeutics, Inc.	Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en)	2007-06-22	2012-10-09	Ptc Therapeutics, Inc.	Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
NZ584848A (en)	2007-09-28	2012-09-28	Intrexon Corp	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
ES2548377T3 (es)	2008-10-27	2015-10-16	Revivicor, Inc.	Ungulados inmunodeprimidos
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3858993A1 (en)	2015-10-09	2021-08-04	Sarepta Therapeutics, Inc.	Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2025110681A1 (ko) *	2023-11-20	2025-05-30	㈜라트바이오	신규 프로모터

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6465239B1 (en) *	1993-03-19	2002-10-15	The John Hopkins University School Of Medicine	Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
JPH09507829A (ja) *	1993-03-19	1997-08-12	ジョーンズホプキンスユニバーシティースクールオブメディシン	増殖分化因子−８
AU6274298A (en) *	1997-02-05	1998-08-25	Johns Hopkins University School Of Medicine, The	Growth differentiation factor-8
US6555672B1 (en) *	1998-07-15	2003-04-29	Metamorphix, Inc.	Growth differentiation factor promoter and uses therefor
ZA200003786B (en)	1999-07-30	2002-01-21	Pfizer Prod Inc	Myostatin regulatory region, nucleotide sequence determination and methods for its use.

1999
- 1999-06-10 US US09/329,685 patent/US6284882B1/en not_active Expired - Fee Related
2000
- 2000-06-09 WO PCT/US2000/015868 patent/WO2000077206A2/en not_active Ceased
- 2000-06-09 DE DE60019586T patent/DE60019586T2/de not_active Expired - Lifetime
- 2000-06-09 JP JP2001503650A patent/JP4625602B2/ja not_active Expired - Fee Related
- 2000-06-09 MX MXPA01012665A patent/MXPA01012665A/es active IP Right Grant
- 2000-06-09 AT AT00941296T patent/ATE293691T1/de not_active IP Right Cessation
- 2000-06-09 ES ES00941296T patent/ES2240108T3/es not_active Expired - Lifetime
- 2000-06-09 PT PT00941296T patent/PT1185649E/pt unknown
- 2000-06-09 EP EP00941296A patent/EP1185649B1/en not_active Expired - Lifetime
- 2000-06-09 CA CA2375820A patent/CA2375820C/en not_active Expired - Fee Related
2001
- 2001-07-09 US US09/901,511 patent/US6399312B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60019586T2 (de)	2006-03-09
MXPA01012665A (es)	2002-07-22
WO2000077206A2 (en)	2000-12-21
ES2240108T3 (es)	2005-10-16
JP2003528574A (ja)	2003-09-30
CA2375820C (en)	2010-07-27
DE60019586D1 (de)	2005-05-25
ATE293691T1 (de)	2005-05-15
US6399312B2 (en)	2002-06-04
WO2000077206A3 (en)	2001-12-06
US6284882B1 (en)	2001-09-04
EP1185649A2 (en)	2002-03-13
JP4625602B2 (ja)	2011-02-02
EP1185649B1 (en)	2005-04-20
US20010049435A1 (en)	2001-12-06
CA2375820A1 (en)	2000-12-21

Publication	Publication Date	Title
PT1185649E (pt)	2005-08-31	Promotor do gene da miostatina e inibicao da sua activacao
ATE244717T1 (de)	2003-07-15	Inhibitoren des impdh-enzyms
AP9901674A0 (en)	1999-12-31	Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
ECSP034603A (es)	2003-06-25	Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares
NO995544L (no)	2000-01-10	Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
BR9811099A (pt)	2002-05-14	Inibidores de urocinase
AU3652102A (en)	2002-06-11	Compounds and their uses
IS5985A (is)	2001-06-28	Frumuviðloðunar-bælandi bólgu-eyðandi og ónæmisbælandi efnasambönd
PT1250340E (pt)	2005-04-29	Metodos e compostos para inibicao de mrp1
WO2001056573A8 (en)	2001-11-01	Use of cox-2 inhibitors as gastroprokinetics
EP1244452A4 (en)	2003-01-15	UROTENSIN II RECEPTOR ANTAGONISTS
TW200515917A (en)	2005-05-16	Methods and compositions for the generation of a protective immune response against SARS-COV
ATE303362T1 (de)	2005-09-15	Chalcon-derivate mit antiproliferativer aktivität
ATE516027T1 (de)	2011-07-15	Orazamid orotat zur vorbeugung von leberschäden
ATE443044T1 (de)	2009-10-15	Tace inhibitoren
MXPA02006167A (es)	2004-02-26	Promocion de la angiogenesis con survivina.
IL144199A0 (en)	2002-05-23	Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
EA200100930A1 (ru)	2002-02-28	Способ лечения хозл
AR026901A1 (es)	2003-03-05	Peptidos con n-alquilacion que tienen actividad antiangiogenica
DE59809283D1 (de)	2003-09-18	Inhibitoren für den urokinaserezeptor
ATE305517T1 (de)	2005-10-15	Neurotrypsin
WO2004060878A3 (en)	2005-01-27	Inhibitors of phosphatases
WO2001004354A3 (en)	2001-08-16	Use of ras inhibitors of inhibiting muscle atrophy
PT1276722E (pt)	2006-07-31	Inibidores de naftamidina-uroquinase
EP1201764A3 (en)	2004-01-07	Assays for identifying phosphatase inhibitors